Skip to main content

Chronic Graft Versus Host Disease

12
Pipeline Programs
14
Companies
19
Clinical Trials
7 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
2
4
1
1
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
467%
Monoclonal Antibody
233%
+ 14 programs with unclassified modality

On Market (1)

Approved therapies currently available

AbbVie
IMBRUVICAApproved
ibrutinib
AbbVie
Kinase Inhibitor [EPC]oral2013
2.4B Part D

Competitive Landscape

14 companies ranked by most advanced pipeline stage

AbbVie
AbbVieNORTH CHICAGO, IL
2 programs
1
1
1
ibrutinibPhase 3Small Molecule1 trial
IbrutinibPhase 1/2Small Molecule1 trial
Active Trials
NCT03790332Completed59Est. Oct 2025
NCT02959944Completed193Est. Jul 2021
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
1
Biological: mesenchymal stem cellPhase 2/31 trial
Active Trials
NCT01526850Unknown100Est. Jun 2014
Incyte
IncyteDE - Wilmington
3 programs
1
2
AxatilimabPhase 2Monoclonal Antibody1 trial
AxatilimabPhase 2Monoclonal Antibody2 trials
FostamatinibPhase 1Small Molecule
Active Trials
NCT06663722Recruiting49Est. May 2030
NCT07511062Not Yet Recruiting32Est. Aug 2030
NCT07011810Recruiting50Est. Feb 2030
Meiji Seika Pharma
Meiji Seika PharmaJapan - Tokyo
1 program
1
BelumosudilPhase 2
Kite Pharma
Kite PharmaCA - El Segundo
1 program
1
ENTOPhase 21 trial
Active Trials
NCT02701634Terminated66Est. Mar 2018
Pfizer
PfizerNEW YORK, NY
1 program
1
GlasdegibPhase 1/22 trials
Active Trials
NCT04111497Terminated15Est. Aug 2023
NCT03130556Completed24Est. Jul 2017
Iovance Biotherapeutics
1 program
1
Treg-enriched infusionPhase 11 trial
Active Trials
NCT01937468Active Not Recruiting25Est. Dec 2026
BioTherapeutics Inc
BioTherapeutics IncVA - Blacksburg
1 program
1
Treg-enriched infusionPhase 1
Chia Tai TianQing Pharmaceutical Group
2 programs
TQ05105 TabletPHASE_1_22 trials
TQ05105 tabletsPHASE_22 trials
Active Trials
NCT07480824Recruiting24Est. Dec 2026
NCT04944043Active Not Recruiting45Est. Dec 2026
NCT07551427Not Yet Recruiting51Est. Jun 2029
+1 more trials
Sanofi
SanofiPARIS, France
2 programs
BelumosudilPHASE_21 trial
BelumosudilPHASE_21 trial
Active Trials
NCT07116031Recruiting37Est. Feb 2031
NCT05996627Recruiting82Est. Nov 2028
Gilead Sciences
Gilead SciencesFOSTER CITY, CA
2 programs
ENTOPHASE_2
ENTOPHASE_2
Parexel
ParexelMA - Boston
1 program
ECP MethoxsalenPHASE_11 trial
Active Trials
NCT01380535Completed60Est. Mar 2015
Rigel Pharmaceuticals
Rigel PharmaceuticalsSOUTH SAN FRANCISCO, CA
1 program
FostamatinibPHASE_1Small Molecule1 trial
Active Trials
NCT06233110Recruiting30Est. Jul 2029
Genentech
GenentechCA - Oceanside
1 program
Laboratory Biomarker AnalysisPHASE_21 trial
Active Trials
NCT02337517Terminated6Est. Jun 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
AbbVieibrutinib
UNION therapeuticsBiological: mesenchymal stem cell
Chia Tai TianQing Pharmaceutical GroupTQ05105 tablets
SanofiBelumosudil
IncyteAxatilimab
IncyteAxatilimab
Chia Tai TianQing Pharmaceutical GroupTQ05105 tablets
SanofiBelumosudil
Kite PharmaENTO
GenentechLaboratory Biomarker Analysis
Chia Tai TianQing Pharmaceutical GroupTQ05105 Tablet
PfizerGlasdegib
AbbVieIbrutinib
IncyteAxatilimab
Chia Tai TianQing Pharmaceutical GroupTQ05105 Tablet

Showing 15 of 19 trials with date data

Clinical Trials (19)

Total enrollment: 1,000 patients across 19 trials

Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)

Start: May 2017Est. completion: Jul 2021193 patients
Phase 3Completed
NCT01526850UNION therapeuticsBiological: mesenchymal stem cell

Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Chronic Graft Versus Host Disease

Start: Feb 2012Est. completion: Jun 2014100 patients
Phase 2/3Unknown

A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk Myelofibrosis

Start: May 2026Est. completion: Jun 202951 patients
Phase 2Not Yet Recruiting

A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)

Start: Dec 2025Est. completion: Feb 203137 patients
Phase 2Recruiting

Axatilimab for Sclerotic Chronic Graft-versus-Host Disease

Start: Aug 2025Est. completion: Feb 203050 patients
Phase 2Recruiting

Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease

Start: May 2025Est. completion: May 203049 patients
Phase 2Recruiting

A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease

Start: May 2024Est. completion: Apr 202652 patients
Phase 2Recruiting

Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease

Start: Dec 2023Est. completion: Nov 202882 patients
Phase 2Recruiting

Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD)

Start: May 2016Est. completion: Mar 201866 patients
Phase 2Terminated
NCT02337517GenentechLaboratory Biomarker Analysis

Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease

Start: Sep 2015Est. completion: Jun 20186 patients
Phase 2Terminated

A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease

Start: Jun 2021Est. completion: Dec 202645 patients
Phase 1/2Active Not Recruiting

Glasdegib for Chronic Graft-Versus-Host Disease

Start: Dec 2019Est. completion: Aug 202315 patients
Phase 1/2Terminated

Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)

Start: Nov 2018Est. completion: Oct 202559 patients
Phase 1/2Completed

Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML

Start: Aug 2026Est. completion: Aug 203032 patients
Phase 1Not Yet Recruiting

To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment Subjects

Start: Apr 2026Est. completion: Dec 202624 patients
Phase 1Recruiting

Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD

Start: Oct 2025Est. completion: Jul 202930 patients
Phase 1Recruiting

A Study Of Glasdegib In Healthy Volunteers To Establish The Bioequivalence Of The Phase 2 Formulation To The ICH Formulation

Start: May 2017Est. completion: Jul 201724 patients
Phase 1Completed

Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease

Start: Nov 2013Est. completion: Dec 202625 patients
Phase 1Active Not Recruiting
NCT01380535ParexelECP Methoxsalen

Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD)

Start: Nov 2011Est. completion: Mar 201560 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
7 actively recruiting trials targeting 1,000 patients
14 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.